Extended Data Fig. 3: CyTOF results for all patients.
From: A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial
a. Cytometry by time of flight (CyTOF) analysis of baseline (B) and post-treatment (P) PBMCs cultured with vehicle, an irrelevant peptide (KRAS G12D), or the full length FLC peptide, shows that treatment was associated with an expansion of CD4+ T helper cells, as well as activated CD8+ cytotoxic T cells. b. Quantification of expanded T helper cells and cytotoxic T cells from FLC peptide stimulated populations with TIM3hiPD1hi and TIM3loPD1hi expression. Paired two-sided t-test, ns p > 0.05. ThEFF, effector T cells, ThEM, effector memory T cells. UnB, unstimulated Baseline, Un P, unstimulated post- treatment.
